These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 27758148

  • 1. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections.
    Buckman SA, Krekel T, Muller AE, Mazuski JE.
    Expert Opin Pharmacother; 2016 Dec; 17(17):2341-2349. PubMed ID: 27758148
    [Abstract] [Full Text] [Related]

  • 2. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
    Mawal Y, Critchley IA, Riccobene TA, Talley AK.
    Expert Rev Clin Pharmacol; 2015 Dec; 8(6):691-707. PubMed ID: 26420166
    [Abstract] [Full Text] [Related]

  • 3. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R, Park TE, Moy S.
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [Abstract] [Full Text] [Related]

  • 4. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ, Rybak JM, Rybak MJ.
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [Abstract] [Full Text] [Related]

  • 5. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
    Shirley M.
    Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
    [Abstract] [Full Text] [Related]

  • 6. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB.
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [Abstract] [Full Text] [Related]

  • 7. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
    Falcone M, Paterson D.
    J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
    [Abstract] [Full Text] [Related]

  • 8. Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.
    Chahine EB, Sourial M, Ortiz R.
    Consult Pharm; 2015 Dec; 30(12):695-705. PubMed ID: 26671269
    [Abstract] [Full Text] [Related]

  • 9. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP.
    Expert Opin Investig Drugs; 2015 Dec; 24(9):1261-73. PubMed ID: 26145447
    [Abstract] [Full Text] [Related]

  • 10. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.
    Qin X, Tran BG, Kim MJ, Wang L, Nguyen DA, Chen Q, Song J, Laud PJ, Stone GG, Chow JW.
    Int J Antimicrob Agents; 2017 May; 49(5):579-588. PubMed ID: 28363526
    [Abstract] [Full Text] [Related]

  • 11. Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
    Hidalgo JA, Vinluan CM, Antony N.
    Drug Des Devel Ther; 2016 May; 10():2379-86. PubMed ID: 27528799
    [Abstract] [Full Text] [Related]

  • 12. Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.
    Cheng K, Newell P, Chow JW, Broadhurst H, Wilson D, Yates K, Wardman A.
    Drug Saf; 2020 Aug; 43(8):751-766. PubMed ID: 32602065
    [Abstract] [Full Text] [Related]

  • 13. Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.
    Bradley JS, Broadhurst H, Cheng K, Mendez M, Newell P, Prchlik M, Stone GG, Talley AK, Tawadrous M, Wajsbrot D, Yates K, Zuzova A, Gardner A.
    Pediatr Infect Dis J; 2019 Aug; 38(8):816-824. PubMed ID: 31306396
    [Abstract] [Full Text] [Related]

  • 14. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
    Santevecchi BA, Smith TT, MacVane SH.
    Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
    [Abstract] [Full Text] [Related]

  • 15. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
    Stone GG, Newell P, Gasink LB, Broadhurst H, Wardman A, Yates K, Chen Z, Song J, Chow JW.
    J Antimicrob Chemother; 2018 Sep 01; 73(9):2519-2523. PubMed ID: 29912399
    [Abstract] [Full Text] [Related]

  • 16. Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets.
    Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK.
    Antimicrob Agents Chemother; 2017 Jun 01; 61(6):. PubMed ID: 28348155
    [Abstract] [Full Text] [Related]

  • 17. Aztreonam-avibactam for the treatment of intra-abdominal infections.
    Delp H, Gibson GA, Buckman SA.
    Expert Opin Pharmacother; 2024 Oct 01; 25(14):1867-1872. PubMed ID: 39327993
    [Abstract] [Full Text] [Related]

  • 18. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
    MacGowan A, Tomaselli S, Noel A, Bowker K.
    J Antimicrob Chemother; 2017 Mar 01; 72(3):762-769. PubMed ID: 28039276
    [Abstract] [Full Text] [Related]

  • 19. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL, Mahoney MV, Hirsch EB.
    Int J Antimicrob Agents; 2015 Sep 01; 46(3):266-71. PubMed ID: 26143591
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
    Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J.
    Clin Infect Dis; 2016 Jun 01; 62(11):1380-1389. PubMed ID: 26962078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.